Ranbaxy Laboratories Ltd has entered into a co-marketing agreement with Ferring International of Switzerland, a specialty biopharmaceutical firm, for its product Desmopressin; a structural analogue of the pituitary hormone arginine vasopressin. The product is indicated in the treatment of Nocturia, a condition commonly seen in paediatric and geriatric patients.
Desmopressin, an orginal research product of Ferring International, is available in tables and sprays, and is currently marketed by the company's Indian subsidiary. This new co-marketing arrangement will leverage Ranbaxy's marketing and distribution network and will be sold under the brand name Adiuretin.
Commenting on the development, Mr. Sanjeev Dani Regional Director- India & Middle East of the Company said,
"This is a strategic move by Ranbaxy to in-license differentiated products for the Indian market. In a short span of 3 years Ranbaxy has become a leader in the urology segment and this agreement further helps to consolidate out position as a provider of trusted, high quality medicines to the India market," commented Sanjeev Dani, regional director, India and Middle East, Ranbaxy.